USL 311

Drug Profile

USL 311

Alternative Names: USL311

Latest Information Update: 10 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer Upsher-Smith
  • Class Antineoplastics
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 16 May 2016 USL 311 receives Orphan Drug status for Glioblastoma in USA
  • 01 Apr 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease, Combination therapy, Monotherapy) in USA (unspecified route) (NCT02765165)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top